88IV - <600196.CN> - Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Share This

Create Your Own Business Intelligence Website
Input the stock code or the company name		Search

Basic Datum
Company name	资产收益	每股收益	每股资产	收入增长	利润增长
Fosun Pharma	3.36%	0.18	5.24	13.18%	32.77%

Company name	价位	五日表现	五日换手	十日表现	十日换手
Fosun Pharma	33.81	-0.88%	5.32%	0.83%	9.67%

所属板块：分拆上市医药参股金融新上海新能源沪深300 生物医药锂电池长三角

Related links
www.fosunpharma.com

Related news
復星醫藥(02196.HK)：復宏漢霖獲藥品臨床試驗批准
格隆匯4月17日亅復星醫藥(600196)(02196.HK)發布公告，公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(以下合稱「復宏漢霖」)於近日收到國家藥監局關於同意其自主研發的HLX53(即抗TIGIT的Fc融合蛋白)聯合漢斯狀?(即斯魯利單抗注射液)和漢貝泰?(即貝伐珠單抗注射液)一線治療局部晚期或轉移性肝細胞癌(HCC)開展臨床試驗的批准
復星醫藥(600196.SH)：膦甲酸鈉注射液注冊申請獲受理
智通財經APP訊，復星醫藥(600196)(600196.SH)公告，公司控股子公司桂林南藥股份有限公司的膦甲酸鈉注射液(以下簡稱「該新藥」)的藥品注冊申請於近日獲國家藥品監督管理局受理。據悉，該新藥系化學藥品，擬用於(1)獲得性免疫缺陷綜合征(AIDS)患者的巨細胞病毒性(CMV)視網膜炎;(2)免疫功能低下患者的耐阿昔洛韋單純皰疹病毒性(HSV)的皮膚黏膜感染
復星醫藥(600196.SH)：控股子公司復宏漢霖(0269...
智通財經APP訊，復星醫藥(600196)(600196.SH)公告，公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(「復宏漢霖」)於近日收到國家藥品監督管理局關於同意其自主研發的HLX53(即抗TIGIT的Fc融合蛋白)聯合漢斯狀(即斯魯利單抗注射液)和漢貝泰(即貝伐珠單抗注射液)一線治療局部晚期或轉移性肝細胞癌(HCC)(「該治療方案」)開展臨床試驗的批准
≫More

Comment

Top Gain / Loss	Show All Charts

Value
Name	Updated	Value	Change	Change %
Fosun Pharma	05-13 15:00	33.81	▼ 0.28	▼ 0.82%
≫More

More Topics：
\| Real Est HK Construction Real Est China Rentals \| REITs Agri Enviro \| fertilizer producers Water \| Util HK Banks \| China Banks \| Insure \| China Finance \| Brokers Consumer \| Food \| Supermarket Diary Education merchant \| Garment \| HK Apparel \| Sports Appl \| Auto \| jewel \| Beauty \| HK retail Shipping \| Shipbuilding \| Harbour \| Highways \| Airlines \| logistics \| Expo \| Textile Paper \| Resource \| Rare Earths \| Steel \| Gold mine \| Mach Petro \| Electricity \| Nuclear power \| New Energy \| gas \| coal Infra \| Railway \| Build Mat \| Cement China IT \| Communication Gambling China Lottery media film Drugs		HK Housing Market \| Real Estate Market \| \| \| \| \| \| HK Stock \| Stock Trend \| capital flow \| A Shares \| ETF \| IPO \| \| Gold \| Gold Jew \| Oil \| Commodity \| G20 \| Top 500 USD \| GBD \| EURO \| Swiss franc \| AUD \| NZD \| CAD \| YEN \| RMB \| Korean Won \| Taiwan Dollar (TWD) iBond \| Emerging markets Lang \| Andy Xie \| Simon Ting \| Law Ka-Chung \| LiuDongliang \| XieXuren \| FanGang \| Mobius \| BillGross \| Roubini \| Faber Financial and political policy \| Central Bank Monetary Policy \| Social Security Fund \| \| \| \|

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.